Interest is finally to beginning to pick up in the European Medicines Agency's pilot project on offering early scientific advice to drug sponsors to support the development of pediatric medicines. The pilot had initially drawn a lukewarm response from pharmaceutical companies, who showed reluctance to discuss their pediatric research plans with the agency at an early stage.
The one-year pilot was launched in June this year to facilitate and encourage dialogue between drug sponsors and the EMA's pediatrics committee, the PDCO, at an early stage of product development "when the pediatric needs
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Pink Sheet for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?